A group representing companies that made copycat versions of Eli Lilly & Co.’s weight-loss drugs sued the US Food and Drug ...

A drug compounding industry group on Monday sued the U.S. Food and Drug Administration over its decision to take Eli Lilly’s ...

The two-year shortage of Eli Lilly’s blockbuster weight-loss and diabetes drugs is over, the U.S. Food and Drug ...

Eli Lilly shares have soared thanks to excitement about the company's position in the weight loss drug market.

Eli Lilly said Wednesday it will invest $4.5 billion to build an advanced pharmaceutical drug manufacturing and development ...

The U.S. Food and Drug Administration said Eli Lilly’s diabetes and weight-loss drugs marketed as Zepbound and Mounjaro are ...

It has the most potent weight-loss shot and a large experimental pipeline, including what is widely expected to be the first ...

Health care stocks underperformed the broader market in 2023, with many companies falling short of their profit targets, and ...

The removal of Zepbound and Mounjaro from the regulator’s shortage list could lead to restrictions on pharmacies making ...

FDA announces Eli Lilly's Tirzepatide is no longer in shortage in the US. Impact on compounded GLP-1s & semaglutide supply.

The San Francisco telehealth company had capitalized on the shortage by making copycat versions of popular brand-name GLP-1 ...

CNBC's Angelica Peebles joins 'Squawk on the Street' to report on Eli Lilly's new investment in a new $4.5 billion research ...